Article info

PDF

Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies

Authors

  • Jennifer E Miller Division of Medical Ethics, Department of Population Health, NYU School of Medicine, New York, USA Bioethics International, New York, USA PubMed articlesGoogle scholar articles
  • Marc Wilenzick International Aids Vaccine Initiative, New York, USA PubMed articlesGoogle scholar articles
  • Nolan Ritcey Bioethics International, New York, USA PubMed articlesGoogle scholar articles
  • Joseph S Ross Section of General Internal Medicine and Robert Wood Johnson Foundation Clinical Scholars Program, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USA Center for Outcomes Research and Evaluation, Yale-New Haven Health, New Haven, Connecticut, USA PubMed articlesGoogle scholar articles
  • Michelle M Mello Stanford Law School and the Department of Health Research and Policy, Stanford University Stanford Law School, Stanford, California, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Jennifer E Miller; jennifer.miller{at}nyumc.org
View Full Text

Citation

Miller JE, Wilenzick M, Ritcey N, et al
Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies

Publication history

  • Received May 26, 2017
  • Revised October 25, 2017
  • Accepted October 31, 2017
  • First published December 5, 2017.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.